193 related articles for article (PubMed ID: 9932162)
1. Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days.
Sessa C; Minoia C; Ronchi A; Zucchetti M; Bauer J; Borner M; de Jong J; Pagani O; Renard J; Weil C; D'Incalci M
Ann Oncol; 1998 Dec; 9(12):1315-22. PubMed ID: 9932162
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: a phase I study.
Kurata T; Tamura T; Sasaki Y; Fujii H; Negoro S; Fukuoka M; Saijo N
Jpn J Clin Oncol; 2000 Sep; 30(9):377-84. PubMed ID: 11095134
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer.
McKeage MJ; Raynaud F; Ward J; Berry C; O'Dell D; Kelland LR; Murrer B; Santabárabara P; Harrap KR; Judson IR
J Clin Oncol; 1997 Jul; 15(7):2691-700. PubMed ID: 9215842
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
Vouillamoz-Lorenz S; Buclin T; Lejeune F; Bauer J; Leyvraz S; Decosterd LA
Anticancer Res; 2003; 23(3C):2757-65. PubMed ID: 12926110
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of oral JM216 given twice daily.
Beale P; Raynaud F; Hanwell J; Berry C; Moore S; Odell D; Judson I
Cancer Chemother Pharmacol; 1998; 42(2):142-8. PubMed ID: 9654114
[TBL] [Abstract][Full Text] [Related]
6. Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo.
McKeage MJ; Kelland LR; Boxall FE; Valenti MR; Jones M; Goddard PM; Gwynne J; Harrap KR
Cancer Res; 1994 Aug; 54(15):4118-22. PubMed ID: 8033145
[TBL] [Abstract][Full Text] [Related]
7. A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration.
McKeage MJ; Mistry P; Ward J; Boxall FE; Loh S; O'Neill C; Ellis P; Kelland LR; Morgan SE; Murrer B
Cancer Chemother Pharmacol; 1995; 36(6):451-8. PubMed ID: 7554035
[TBL] [Abstract][Full Text] [Related]
8. Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study.
Ricart AD; Sarantopoulos J; Calvo E; Chu QS; Greene D; Nathan FE; Petrone ME; Tolcher AW; Papadopoulos KP
Clin Cancer Res; 2009 Jun; 15(11):3866-71. PubMed ID: 19458055
[TBL] [Abstract][Full Text] [Related]
9. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
Wolff I; Bench K; Beijnen JH; Bruntsch U; Cavalli F; de Jong J; Groot Y; van Tellingen O; Wanders J; Sessa C
Clin Cancer Res; 1996 Oct; 2(10):1717-23. PubMed ID: 9816122
[TBL] [Abstract][Full Text] [Related]
10. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule.
Schilder RJ; LaCreta FP; Perez RP; Johnson SW; Brennan JM; Rogatko A; Nash S; McAleer C; Hamilton TC; Roby D
Cancer Res; 1994 Feb; 54(3):709-17. PubMed ID: 8306332
[TBL] [Abstract][Full Text] [Related]
12. Lack of nephrotoxicity of new oral platinum drug JM216 in lung cancer patients.
Fokkema E; de Vries EG; Meijer S; Groen HJ
Cancer Chemother Pharmacol; 2000; 45(1):89-92. PubMed ID: 10647508
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients.
Campone M; Rademaker-Lakhai JM; Bennouna J; Howell SB; Nowotnik DP; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2007 Sep; 60(4):523-33. PubMed ID: 17308894
[TBL] [Abstract][Full Text] [Related]
14. Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex.
Sessa C; Capri G; Gianni L; Peccatori F; Grasselli G; Bauer J; Zucchetti M; Viganò L; Gatti A; Minoia C; Liati P; Van den Bosch S; Bernareggi A; Camboni G; Marsoni S
Ann Oncol; 2000 Aug; 11(8):977-83. PubMed ID: 11038034
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer.
Fokkema E; Groen HJ; Bauer J; Uges DR; Weil C; Smith IE
J Clin Oncol; 1999 Dec; 17(12):3822-7. PubMed ID: 10577855
[TBL] [Abstract][Full Text] [Related]
16. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
17. An update on satraplatin: the first orally available platinum anticancer drug.
Kelland LR
Expert Opin Investig Drugs; 2000 Jun; 9(6):1373-82. PubMed ID: 11060749
[TBL] [Abstract][Full Text] [Related]
18. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
[TBL] [Abstract][Full Text] [Related]
19. Biotransformation of the platinum drug JM216 following oral administration to cancer patients.
Raynaud FI; Mistry P; Donaghue A; Poon GK; Kelland LR; Barnard CF; Murrer BA; Harrap KR
Cancer Chemother Pharmacol; 1996; 38(2):155-62. PubMed ID: 8616906
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of carboplatin given on a five-day intravenous schedule.
Rozencweig M; Nicaise C; Beer M; Crespeigne N; Van Rijmenant M; Lenaz L; Kenis Y
J Clin Oncol; 1983 Oct; 1(10):621-6. PubMed ID: 6366128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]